Have a feature idea you'd love to see implemented?
Let us know!
FULC Fulcrum Therapeutics Inc
Price (delayed)
$3.24
Market cap
$202.18M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.33
Enterprise value
$123.91M
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine
Highlights
The company's EPS has surged by 81% YoY and by 79% QoQ
Fulcrum Therapeutics's net income has soared by 80% from the previous quarter and by 79% YoY
Key stats
What are the main financial stats of FULC
Market
Valuations
Earnings
Shares outstanding
62.4M
Market cap
$202.18M
Enterprise value
$123.91M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.74
Price to sales (P/S)
2.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.52
Revenue
$81.63M
EBIT
-$20.23M
EBITDA
-$18.34M
Free cash flow
-$12.62M
Per share
Balance sheet
Liquidity
EPS
-$0.33
Free cash flow per share
-$0.2
Book value per share
$4.41
Revenue per share
$1.31
TBVPS
$4.73
Total assets
$294.26M
Total liabilities
$20.47M
Debt
$9.65M
Equity
$273.79M
Working capital
$267.59M
Debt to equity
0.04
Current ratio
22.07
Quick ratio
21.84
Net debt/EBITDA
4.27
Margins
Efficiency
Dividend
EBITDA margin
-22.5%
Gross margin
100%
Net margin
-24.8%
Operating margin
-40.1%
Return on assets
-7.6%
Return on equity
-8.3%
Return on invested capital
-9.3%
Return on capital employed
-7.2%
Return on sales
-24.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FULC stock price
How has the Fulcrum Therapeutics stock price performed over time
Intraday
-0.31%
1 week
-8.73%
1 month
0.93%
1 year
-10.25%
YTD
-52%
QTD
-9.24%
Financial performance
How have Fulcrum Therapeutics's revenue and profit performed over time
Revenue
$81.63M
Gross profit
$81.63M
Operating income
-$32.77M
Net income
-$20.23M
Gross margin
100%
Net margin
-24.8%
The net margin has soared by 99% from the previous quarter and by 99% YoY
Fulcrum Therapeutics's operating margin has soared by 99% from the previous quarter and by 99% YoY
Fulcrum Therapeutics's net income has soared by 80% from the previous quarter and by 79% YoY
The company's operating income has surged by 71% QoQ and by 70% YoY
Growth
What is Fulcrum Therapeutics's growth rate over time
Valuation
What is Fulcrum Therapeutics stock price valuation
P/E
N/A
P/B
0.74
P/S
2.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.52
The company's EPS has surged by 81% YoY and by 79% QoQ
FULC's P/B is 72% below its 5-year quarterly average of 2.6 and 56% below its last 4 quarters average of 1.7
The equity has grown by 28% from the previous quarter
The price to sales (P/S) is 98% lower than the last 4 quarters average of 122.5 and 97% lower than the 5-year quarterly average of 83.2
Efficiency
How efficient is Fulcrum Therapeutics business performance
The company's return on sales has surged by 99% QoQ and by 99% YoY
Fulcrum Therapeutics's ROA has soared by 80% from the previous quarter and by 79% YoY
Fulcrum Therapeutics's ROE has soared by 80% from the previous quarter and by 79% YoY
FULC's return on invested capital has surged by 79% year-on-year and by 78% since the previous quarter
Dividends
What is FULC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FULC.
Financial health
How did Fulcrum Therapeutics financials performed over time
FULC's total assets is up by 27% since the previous quarter but it is down by 2% year-on-year
Fulcrum Therapeutics's total liabilities has decreased by 18% YoY but it has increased by 8% from the previous quarter
The debt is 96% less than the equity
The equity has grown by 28% from the previous quarter
The debt has contracted by 21% YoY and by 4.8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.